CML—where do we stand in 2015?

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 103-105

  Hehlmann, Rüdiger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; EDITORIAL; FERTILITY PRESERVATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LONG TERM SURVIVAL; PRIORITY JOURNAL; EVIDENCE BASED MEDICINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL RESEARCH; MORTALITY; TRENDS;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS;

EID: 84926061573     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2331-1     Document Type: Editorial

References (10)

1. Hehlmann et al (2014) J Clin Oncol 32(5):415–23
2. Deininger et al ASH (2009) Abstract. 1126
3. Baccarani et al EHA (2009) Haematologica 94(suppl.2):254 Abstr. 626
4. de Lavallade et al (2008) J Clin Oncol 26(20):3358–63
5. Cervantes et al (2010) Haematologica 95(8):1317–24
6. Baccarani et al (2014) Int J Hematol 99(5):616–24
7. Sasaki et al ASCO (2014) Abstract 7024
8. Gambacorti-Passerini et al (2011) J Natl Cancer Inst 103(7):553–61
9. Larson et al ASCO (2014) Abstract 7073
10. Cortes et al ASH (2014) Abstract 152